TGF-β signaling regulates CD8+ T cell responses to high- and low-affinity TCR interactions

被引:11
作者
Mehal, WZ
Sheikh, SZ
Gorelik, L
Flavell, RA
机构
[1] Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT 06520 USA
[3] Biogen Inc, Cambridge, MA USA
[4] Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA
关键词
antigen/peptides/epitopes; cellular activation; rodent; T lymphocytes;
D O I
10.1093/intimm/dxh233
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Absence of transforming growth factor-beta (TGF-beta) signaling to T cells in mice results in an increase in T cell numbers, an activated CD44 high, CD69-, CD25- T cell phenotype and a T cell-mediated injury to many organs. It is not known if such T cell activation in the absence of TGF-beta signaling is spontaneous or due to aberrant T cell responses to a physiological stimulus. We used adoptive transfer of CD8+ T cells from mice double transgenic for the OT-1 TCR and the TGF-beta 1-dominant negative transgene [OT-dominant-negative receptor (DNR)] to investigate the role of TGF-beta in regulating CD8+ T cell activation in vivo. The activation and expansion of single-transgenic OT and double-transgenic OT-DNR cells to oral antigens, high-affinity and low-affinity peptides were indistinguishable. Activation with high-affinity peptide and CFA however resulted in greater expansion of OT-DNR cells in comparison to OT cells. Low-affinity peptide and adjuvant did not result in OT cell activation or expansion but results in up-regulation of CD44 on OT-DNR cells. These data show that TGF-beta functions in vivo to limit the scale of CD8+ T cell expansion after high-affinity peptide-MHC interactions. TGF-beta also limits T cell activation to the highest affinity peptide-MHC interactions. The increase in T cell number and activation present in TGF-beta-deficient and TGF-beta DNR-expressing mice may be due to the loss of these two phenomena.
引用
收藏
页码:531 / 538
页数:8
相关论文
共 36 条
[1]   Coordinate cytokine gene expression in vivo following induction of tuberculous pleurisy in guinea pigs [J].
Allen, SS ;
McMurray, DN .
INFECTION AND IMMUNITY, 2003, 71 (08) :4271-4277
[2]   In vivo antagonism of a T cell response by an endogenously expressed ligand [J].
Basu, D ;
Williams, CB ;
Allen, PM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (24) :14332-14336
[3]  
Billiau A, 2001, J LEUKOCYTE BIOL, V70, P849
[4]   A bone marrow-derived APC in the gut-associated lymphoid tissue captures oral antigens and presents them to both CD4+ and CD8+ T cells [J].
Blanas, E ;
Davey, GM ;
Carbone, FR ;
Heath, WR .
JOURNAL OF IMMUNOLOGY, 2000, 164 (06) :2890-2896
[5]   TGF-β1 regulates lymphocyte homeostasis by preventing activation and subsequent apoptosis of peripheral lymphocytes [J].
Bommireddy, R ;
Saxena, V ;
Ormsby, I ;
Yin, MY ;
Boivin, GP ;
Babcock, GF ;
Singh, RR ;
Doetschman, T .
JOURNAL OF IMMUNOLOGY, 2003, 170 (09) :4612-4622
[6]   The liver as a site of T-cell apoptosis: graveyard, or krilling field? [J].
Crispe, IN ;
Dao, T ;
Klugewitz, K ;
Mehal, WZ ;
Metz, DP .
IMMUNOLOGICAL REVIEWS, 2000, 174 :47-62
[7]   Innate CD4+CD25+ regulatory T cells are required for oral tolerance and inhibition of CD8+ T cells mediating skin inflammation [J].
Dubois, B ;
Chapat, L ;
Goubier, A ;
Papiernik, M ;
Nicolas, JF ;
Kaiserlian, D .
BLOOD, 2003, 102 (09) :3295-3301
[8]   Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease [J].
Gorelik, L ;
Flavell, RA .
IMMUNITY, 2000, 12 (02) :171-181
[9]   Levels of transforming growth factor β and transforming growth factor β receptors in rat liver during growth, regression by apoptosis and neoplasia [J].
Grasl-Kraupp, B ;
Rossmanith, W ;
Ruttkay-Nedecky, B ;
Müllauer, L ;
Kammerer, B ;
Bursch, W ;
Schulte-Hermann, R .
HEPATOLOGY, 1998, 28 (03) :717-726
[10]   OIL-INDUCED ARTHRITIS IN DA RATS - TISSUE DISTRIBUTION OF ARTHRITOGENIC C-14-LABELED HEXADECANE [J].
KLEINAU, S ;
DENCKER, L ;
KLARESKOG, L .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1995, 17 (05) :393-&